Details of the Drug

General Information of Drug (ID: DMNI3U2)

Drug Name

ZIMELIDINE

Synonyms

Prestwick0_000092; Prestwick1_000092; 56775-88-3; AC1L26VA; NCIStruc1_001846; NCIStruc2_001359; SPBio_001983; 2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-; CTK1F3832; OYPPVKRFBIWMSX-UHFFFAOYSA-N; DB04832; NCI60_002580; FT-0675907; N,N-dimethyl-3-(4-bromophenyl)-3-(pyrid-3-yl)allylamine; N,N-dimethyl-3-(4-bromophenyl)-3-(3-pyridyl)-allylamine; (Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Withdrawn from market	[1]
Major depressive disorder	6A70.3	Withdrawn from market	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

317.22

Logarithm of the Partition Coefficient (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 13.8 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 8.4 +/- 2.0 hours [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.086% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.8 L/kg [3]

Chemical Identifiers

Formula: C16H17BrN2
IUPAC Name: (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
Canonical SMILES: CN(C)C/C=C(/C1=CC=C(C=C1)Br)\\C2=CN=CC=C2
InChI: InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
InChIKey: OYPPVKRFBIWMSX-SXGWCWSVSA-N

Cross-matching ID

PubChem CID: 5365247
ChEBI ID: CHEBI:92824
CAS Number: 56775-88-3
DrugBank ID: DB04832
TTD ID: D0C1XS

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[5]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[5]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[6]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[5]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Gene/Protein Processing	[6]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Gene/Protein Processing	[5]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[5]
Lanosterol synthase (LSS)	OT9W2SFH	LSS_HUMAN	Gene/Protein Processing	[6]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Gene/Protein Processing	[6]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

06 Mental, behavioural or neurodevelopmental disorder

Disease Class

ICD-11: 6A20 Schizophrenia

The Studied Tissue

Pre-frontal cortex

The Studied Disease

Major depressive disorder [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	1.17E-01	0.07	0.59

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem. 1984 Nov;27(11):1508-15.
5	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
6	Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.